Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GUJTHEM.NS
HoldPremium GrowerGujarat Themis Biosyn Limited · Healthcare · India · $622M · Avg Vol: $2M/d
52
StockRankGet insider-trade alerts
Q
55
V
12
M
79
P/E (TTM)
95.9x
ROE
16.2%
D/E
0.6x
Dividend %
0.2%
COMPANY DESCRIPTION
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India and Japan. The company offers bulk drugs on job work basis in India.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.5B | 1.7B | 1.5B | 1.7B | 3.8% | 1.7B |
| EPS (INR) | 5.32 | 5.43 | 4.48 | 4.28 | -7.0% | 4.51 |
| Shares | 109.0M | 109.0M | 109.0M | 109.0M | 0.0% | 130.2M |
| Debt | 4.2M | 27.7M | 304.7M | 1.6B | 628.2% | 1.6B |
| Equity | 1.5B | 2.0B | 2.5B | 2.9B | 24.5% | — |
| Op CF | 394.8M | 642.1M | 910.3M | 487.8M | 7.3% | 489.4M |
| Inv CF | -204.1M | -552.1M | -1.1B | -1.7B | — | — |
| Fin CF | -132.7M | -85.9M | 260.1M | 1.1B | — | — |
Loading 1Y...
PRICE (1Y)+22.5%
SMA 50SMA 200
Close
$4.51
RSI (14)
66.6
52W High
$5.02
From 52W High
0.9%
SCORE BREAKDOWN
Quality
55
ROIC
16.5%86.0
ROE
16.2%83.8
GP/Assets
23.1%50.3
Op. Margin
38.4%96.3
FCF/Assets
-24.6%17.3
Piotroski
549.3
Int. Cover
14.9x67.9
D/E Ratio
0.56x26.6
Current Ratio
1.12x14.1
Value
12
P/E (TTM)
95.9x9.5
EV/EBITDA
61.6x9.2
P/FCF
—N/A
P/B
16.3x6.9
P/S
32.3x11.9
Div Yield
0.2%3.6
Momentum
79
52W High %
90%84.0
RS 6M
52%91.5
SMA 50/200
1.05x67.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
22%57.1
FUNDAMENTALS
Market Cap
$622M
P/E (Forward)
—
Gross Margin
66.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GUJTHEM.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GUJTHEM.NS | Gujarat Themis Biosyn Limited(you) | $622M | 52 | Hold |
| ORCHPHARMA.NS | Orchid Pharma Limited | $517M | 45 | Hold |
| AARTIPHARM.NS | Aarti Pharmalabs Limited | $829M | 65 | Buy |
| INDOCO.NS | Indoco Remedies Limited | $237M | 57 | Hold |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 71 | Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| NOVARTIND.NS | Novartis India Limited | $475M | 30 | Sell |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 55 | Hold |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| SUVEN.NS | Suven Life Sciences Limited | $1.1B | 34 | Sell |
Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%